VEGF、MMP及IL-6相关指标的表达与非霍奇金淋巴瘤的相关性

Correlation between expression of VEGF, MMP and IL-6 related parameters and non-Hodgkin lymphoma

目的观察血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)、白细胞介素-6(IL-6)的表达,并探讨其与非霍奇金淋巴瘤(NHL)的关系。方法选择2010年1月至2013年12月在我院肿瘤化疗科接受治疗的NHL患者61例作为观察组,选择同期在我院接受治疗的良性淋巴结病变患者50例作为对照组。比较两组患者的VEGF、MMP-9及IL-6表达情况,同时分析其与不同病理的关系。结果观察组患者的VEGF、MMP-9及IL-6阳性表达率分别为75.41%(46/61)、63.93%(39/61)、54.10%(33/61),均明显高于对照组的14.00%(14/50)、8.00%(4/50)、4.00%(2/50),差异均有统计学意义(P<0.05);在侵袭性病理分型、Ⅲ~Ⅳ期临床分期、肿瘤≥3 cm、高度恶化、LDH升高患者中VEGF表达阳性率更高,差异均有统计学意义(85.11%vs 42.86%,95.83%vs 35.14%,94.12%vs 68.18%,91.43%vs 53.85%,94.74%vs 61.90%,均P<0.05)。在Ⅲ~Ⅳ期临床分期、肿瘤≥3 cm、高度恶化患者中MMP-9表达阳性率更高,差异均有统计学意义(91.67%vs 18.92%,88.24%vs 54.55%,82.86%vs 38.46%,均P<0.05)。在Ⅲ~Ⅳ期临床分期以及肿瘤≥3 cm患者中IL-6表达为阳性的比例更大,差异均有统计学意义(87.50%vs 32.43%,76.47%vs 45.45%,均P<0.05)。结论 NHL患者的VEGF、MMP-9及IL-6均呈现高水平表达,同时与病理分型、恶化程度、肿瘤大小等存在显著的关系,临床上可以根据这些指标进行肿瘤治疗及预后判断,具有较高的应用价值。

Objective To observe the expression of vascular endothelial growth factor(VEGF), matrix metalloproteinase-9(MMP-9) and interleukin-6(IL-6), and to investigate their relationship with non-Hodgkin’s lymphoma.Methods Sixty-one patients with non-Hodgkin lymphoma(NHL) were selected as the observation group and 50 patients with benign lymph node disease were enrolled as the control group(with hospitalized time limited from January2010 to December 2013). The expression of VEGF, MMP-9 and IL-6 were compared between the two groups, and the relationships between them and different pathological changes were analyzed. Results The positive expression rate of VEGF, MMP-9 and IL-6 were significantly higher in the observation group than the control group [75.41%(46/61) vs14.00%(14/50), 63.93%(39/61) vs 8.00%(4/50), 54.10%(33/61) vs 4.00%(2/50), P<0.05]. The VEGF positive expression rates of patients with invasive pathological typing, Ⅲ~Ⅳ clinical stage, tumor≥3 cm, high deterioration, elevated LDH were significantly higher(85.11% vs 42.86%, 95.83% vs 35.14%, 94.12% vs 68.18%, 91.43% vs 53.85%, 94.74% vs61.90%, P<0.05). The MMP-9 positive expression rate of patients with Ⅲ~Ⅳ clinical stage, tumor≥3 cm, high deterioration were significantly higher(91.67% vs 18.92%, 88.24% vs 54.55%, 82.86% vs 38.40%, P<0.05). The IL-6 positive expression rate of patients with Ⅲ~Ⅳ clinical stage, tumor≥3 cm were significantly higher(87.50% vs 32.43%, 76.47%vs 45.45%, P<0.05). Conclusion VEGF, MMP-9, IL-6 in NHL patients show a high level of expression, and they have significant relationships with pathological type, deterioration degree and tumor size. These indicators can be used for tumor treatment and prognosis evaluation, which has great application value.